戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and polarization, proplatelet formation, and thrombopoiesis.
2 al MT bands; thus, SLPI is not essential for thrombopoiesis.
3 instructive for megakaryocyte maturation and thrombopoiesis.
4 (NF-E2), a transcription factor required for thrombopoiesis.
5 itor the DMS during megakaryocytopoiesis and thrombopoiesis.
6 ibute to normal megakaryocyte maturation and thrombopoiesis.
7 ci to track donor-derived erythropoiesis and thrombopoiesis.
8  role of NO in megakaryocyte development and thrombopoiesis.
9 y also provide novel molecular insights into thrombopoiesis.
10 mbocytopenia, and measurement of the rate of thrombopoiesis.
11 te to our understanding of the regulation of thrombopoiesis.
12 and a significantly increased extramedullary thrombopoiesis.
13 larger platelets, rather than suppression of thrombopoiesis.
14 ibution of these cytokines to suppression of thrombopoiesis.
15 ncipal regulator of megakaryocytopoiesis and thrombopoiesis.
16 Ks, unraveled CK1alpha as a prerequisite for thrombopoiesis.
17 hepatic thrombopoietin (TPO) production, and thrombopoiesis.
18 ve manner resulting in overall inhibition of thrombopoiesis.
19 s while activating an alternative pathway of thrombopoiesis.
20 lium and the microvascular structure support thrombopoiesis.
21  ikzf1, irf5, irf8, and ikzf1 play a role in thrombopoiesis.
22 megakaryocyte specification, maturation, and thrombopoiesis.
23 expression would affect megakaryopoiesis and thrombopoiesis.
24 ing that RUNX1B can regulate endomitosis and thrombopoiesis.
25 ematopoietic lineage commitment and enhanced thrombopoiesis.
26 grin deletion, specifically in MKs, restores thrombopoiesis.
27 led a previously unappreciated complexity in thrombopoiesis.
28 ys a major role in MK membrane formation and thrombopoiesis.
29 tional repressor of adult erythropoiesis and thrombopoiesis.
30 r niche, the site of terminal maturation and thrombopoiesis.
31 ly impaired demarcation system formation and thrombopoiesis.
32 and synergistic effect with c-Mpl ligands on thrombopoiesis.
33 lar proplatelet shedding, the final stage of thrombopoiesis.
34 ion, itself controlling megakaryopoiesis and thrombopoiesis.
35 telet count was compensated for by increased thrombopoiesis.
36 use bone marrows revealed exceedingly active thrombopoiesis.
37 oidal endothelial cells (BMECs), stimulating thrombopoiesis.
38  randomly transfer, mRNA to platelets during thrombopoiesis.
39 yet another function of this lipid mediator: thrombopoiesis.
40 i-D and IVIG, although IVIG may also enhance thrombopoiesis.
41  of MT regulation during the final stages of thrombopoiesis.
42 beta1 integrin function and signaling during thrombopoiesis.
43 gesting that c-myb is required for sustained thrombopoiesis.
44 ombopoietin-receptor agonist that stimulates thrombopoiesis.
45 ing genetic factors may provide insights for thrombopoiesis.
46 eport a role for the glycoprotein PECAM-1 in thrombopoiesis.
47  pathways that regulate megakaryopoiesis and thrombopoiesis.
48 ad to new molecular approaches to manipulate thrombopoiesis.
49 shear stress is a biophysical determinant of thrombopoiesis.
50 e for PECAM-1 in regulating MK migration and thrombopoiesis.
51 defects in efficient wound healing and rapid thrombopoiesis after acute platelet loss.
52  bone marrow and lung are principal sites of thrombopoiesis although underlying mechanisms remain unc
53 tion was disrupted, resulting in an impaired thrombopoiesis and an abrogated inositol 1,4,5-triphosph
54 ricted beta1 tubulin is required for optimal thrombopoiesis and discoid cell shape.
55         The developed compartmental model of thrombopoiesis and erythropoiesis in a BM toxicity conte
56               A compartmental model of mouse thrombopoiesis and erythropoiesis was set up to predict
57 pathologies involving increased or decreased thrombopoiesis and erythropoiesis, which can aid in dete
58 g of autoantibody development, inhibition of thrombopoiesis and Fcgamma receptor and other polymorphi
59 ld be exploited to study normal and abnormal thrombopoiesis and for in vitro platelet production.
60 on is sufficient to elicit severe defects in thrombopoiesis and hematopoietic stem cell maintenance a
61 ights into the regulatory networks governing thrombopoiesis and identifies Spi1b as a critical regula
62  biology may elucidate mechanisms underlying thrombopoiesis and inform therapeutic strategies for ble
63                                    Defective thrombopoiesis and lack of beta4GalT1 further affect HSC
64 -S1pr1 axis as master regulator of efficient thrombopoiesis and might raise new therapeutic options f
65                 HFRS patients have increased thrombopoiesis and platelet activation, which contribute
66  provide a useful means for evaluating human thrombopoiesis and platelet function in vivo using immun
67                            However, roles in thrombopoiesis and platelet function remain poorly under
68 dentifies previously unrecognized defects in thrombopoiesis and platelet half-life, and demonstrates
69  platelets provides key insights into normal thrombopoiesis and platelet pathologies as SRSF3 RNA tar
70 nctional role of growth hormone in promoting thrombopoiesis and provide a promising avenue for the tr
71   Ablation of neutrophil plucking normalized thrombopoiesis and reduced recurrent thrombosis after my
72  of the specialized microtubules required in thrombopoiesis and that RanBP10 might serve as a molecul
73                       The exact mechanism of thrombopoiesis and the maturation pathways of platelets
74 d an interest to the study of extramedullary thrombopoiesis and therefore MKs have been increasingly
75                         To better understand thrombopoiesis and to develop a potential platelet trans
76  role of CK1alpha for the essential steps of thrombopoiesis and to dissect potential mechanisms of th
77 ain causes for thrombocytopenia are impaired thrombopoiesis and/or increased peripheral destruction o
78 2-dependent endocytosis in megakaryopoiesis, thrombopoiesis, and bone marrow homeostasis.
79 in1-/- mice had defects in megakaryopoiesis, thrombopoiesis, and platelet function, which manifested
80 ate that proteasome function is critical for thrombopoiesis, and suggest inhibition of RhoA signaling
81  (dominant proinflammatory state, inadequate thrombopoiesis, and various B and T lymphocyte disturban
82   The regulation of megakaryocytopoiesis and thrombopoiesis appears to be under the control of an arr
83 ng megakaryopoiesis and platelet production (thrombopoiesis) are still incompletely understood.
84 I interferon secretion and platelet release (thrombopoiesis), as evidenced by partially normalized pl
85 sis appears to result from an enhancement of thrombopoiesis because platelet life span is unchanged.
86  accelerated platelet clearance and impaired thrombopoiesis, but the pathophysiology of ITP has yet t
87 duced by M-CSF was not due to suppression of thrombopoiesis, but to increased activity of the monocyt
88 latelet responses to activation and regulate thrombopoiesis by a negative regulatory effect on premat
89 eal CK2beta as a novel powerful regulator of thrombopoiesis, Ca(2+)-dependent platelet activation, an
90                      The relative sparing of thrombopoiesis can be seen in that only one patient (5%)
91 arrow milieu, it raises the possibility that thrombopoiesis continues in the bloodstream.
92 ided by factor H protection and compensatory thrombopoiesis demonstrates the cooperation between memb
93                               TSPs inhibited thrombopoiesis, diminished bone marrow microvascular rec
94 implicated in a redox-regulated mechanism of thrombopoiesis distinct from the thrombopoietin (TPO)/c-
95  mean platelet volume all indicate increased thrombopoiesis during HFRS.
96 wever, the S1P(4) receptor may also regulate thrombopoiesis during stress-induced accelerated platele
97 irus liganding is dispensable for definitive thrombopoiesis, establishing that fundamentally importan
98 tudy supports a major role for the spleen in thrombopoiesis following engraftment of transplanted ste
99                                 The study of thrombopoiesis has evolved greatly since an era when pla
100 ved in various cellular processes, a role in thrombopoiesis has not been examined.
101 ormation by fragmenting megakaryocytes (MKs; thrombopoiesis) has been extensively studied, the cellul
102 aintenance of bone marrow erythropoiesis and thrombopoiesis have not been defined.
103          This work reveals the mechanisms of thrombopoiesis in lung vasculature and informs approache
104 rved B4galt1 gene as a critical regulator of thrombopoiesis in MKs.
105 ogical conditions, regulate immune cells and thrombopoiesis in the BM, leading to reduced platelet co
106 lation is critical to megakaryocyte (MK) and thrombopoiesis in the context of gene mutations that aff
107 fibroblast growth factor-4 (FGF-4), restored thrombopoiesis in Thpo(-/-) and Mpl(-/-) mice.
108 increase in MK numbers, indicating increased thrombopoiesis in vivo.
109         Possible mediators of suppression of thrombopoiesis include tumor necrosis factor-alpha (TNF-
110 trated the ability to reproduce key steps of thrombopoiesis, including alterations observed in diseas
111 address the current understanding of in vivo thrombopoiesis, including mechanisms of platelet generat
112 entify eight candidate genes associated with thrombopoiesis, including spi1b, a transcription factor
113    Taken together, these studies showed that thrombopoiesis is controlled by a network of transcripti
114                                              Thrombopoiesis is the process by which megakaryocytes re
115 hematopoiesis, although its direct effect on thrombopoiesis is unclear.
116                   Surprisingly, steady-state thrombopoiesis is unperturbed in the absence of caspase-
117 r understanding of their complex biogenesis (thrombopoiesis) is currently incomplete.
118                      Platelet production, or thrombopoiesis, is a critical process involving the diff
119 rombopoietin (TPO), the primary regulator of thrombopoiesis, is also an important, nonredundant media
120 ombopoietin-receptor agonist that stimulates thrombopoiesis, leading to increased platelet production
121                                     Impaired thrombopoiesis leads to increased plasma thrombopoietin
122  of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis, manifested by a significant acceleration
123                                       During thrombopoiesis, maturing megakaryocytes (MKs) migrate wi
124                                       During thrombopoiesis, megakaroycytes undergo extensive cytoske
125                                   Throughout thrombopoiesis megakaryocytes (MKs) form proplatelets wi
126                                       During thrombopoiesis, megakaryocytes (MKs) form proplatelets w
127 n-IIA and implies that myosin-IIA influences thrombopoiesis negatively.
128                Although Rap1 is important in thrombopoiesis, platelet secretion, and surface exposure
129 rmation should provide greater insights into thrombopoiesis, potentially allowing pharmacologic manip
130 mbocytopenia as a consequence of ineffective thrombopoiesis, promoting MK differentiation but also im
131      In conclusion, A-IPF measures real-time thrombopoiesis, providing insight into mechanisms of tre
132 PI1, suggesting evolutionary conservation of thrombopoiesis regulatory mechanisms.
133     The induced perturbation in steady state thrombopoiesis resolves by 4 weeks.
134 marker panel using mouse models of defective thrombopoiesis resulting from absence of GATA1, NF-E2, o
135  2 weeks of murine life, a time during which thrombopoiesis shifted from liver to bone marrow.
136 dexamethasone and anti-D immunoglobulin, and thrombopoiesis-stimulating agents that are in early clin
137      In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients
138  In previous studies romiplostim (AMG531), a thrombopoiesis-stimulating protein, increased platelet c
139             Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has bee
140                     In vivo visualization of thrombopoiesis suggests an important role for shear flow
141 nisms underlying normal megakaryopoiesis and thrombopoiesis that can inform efforts to create alterna
142 e identification of the primary regulator of thrombopoiesis, the Mpl ligand, has led to an explosion
143                                              Thrombopoiesis, the process by which circulating platele
144 ated the role of exogenous ABA in modulating thrombopoiesis, the process of platelet generation.
145                         Our understanding of thrombopoiesis--the formation of blood platelets--has im
146 erence with megakaryocyte motility inhibited thrombopoiesis under physiological conditions and after
147 ion of MK maturation and polarization during thrombopoiesis using a MK/platelet-specific knockout app
148 gosine 1-phosphate (S1P) plays a key role in thrombopoiesis via its receptor S1pr1.
149  of dynamin activity to the latter stages of thrombopoiesis was confirmed by the observation that the
150                                              Thrombopoiesis was determined by quantification of plate
151             To determine the role of DNM2 in thrombopoiesis, we generated Dnm2(fl/fl) Pf4-Cre mice sp
152  advantage of known physiological drivers of thrombopoiesis, we have developed a microfluidic human p
153 he source of intracellular S1P that controls thrombopoiesis, which is associated with SFK expression
154 akaryocytes, the requisite precursor cell in thrombopoiesis, which is the intricate process by which
155 re virtually assured that continued study of thrombopoiesis will yield innumerable clinical and scien
156 tely increase MK-vasculature association and thrombopoiesis with no change in MK number.
157 d splice-blocking PEAR1 morpholinos enhanced thrombopoiesis, without affecting erythropoiesis.

 
Page Top